دورية أكاديمية
Immunotherapy in malignant peritoneal mesothelioma (Review).
| العنوان: | Immunotherapy in malignant peritoneal mesothelioma (Review). |
|---|---|
| المؤلفون: | Alaklabi S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Roy AM; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Skitzki JJ; Department of Surgical Oncology/Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Iyer R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. |
| المصدر: | Molecular and clinical oncology [Mol Clin Oncol] 2023 Feb 22; Vol. 18 (4), pp. 31. Date of Electronic Publication: 2023 Feb 22 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Spandidos Publications UK Ltd Country of Publication: England NLM ID: 101613422 Publication Model: eCollection Cited Medium: Internet ISSN: 2049-9469 (Electronic) Linking ISSN: 20499450 NLM ISO Abbreviation: Mol Clin Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London, UK : Spandidos Publications UK Ltd |
| مستخلص: | Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed. Competing Interests: The authors declare that they have no competing interests. (Copyright © 2020, Spandidos Publications.) |
| References: | Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070) N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) Clin Epidemiol. 2016 Oct 26;8:743-750. (PMID: 27822122) J Immunother. 2022 Feb-Mar 01;45(2):100-103. (PMID: 34723916) Hum Pathol. 2019 May;87:11-17. (PMID: 30794891) J Pathol. 2014 Jan;232(2):199-209. (PMID: 24122236) Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870) Cancers (Basel). 2022 Feb 14;14(4):. (PMID: 35205689) J Thorac Oncol. 2008 Jul;3(7):756-63. (PMID: 18594322) Cancer Biol Ther. 2005 Mar;4(3):342-6. (PMID: 15846066) Ann Surg Oncol. 2016 May;23(5):1496-500. (PMID: 26545374) Anticancer Res. 1994 Jul-Aug;14(4B):1635-9. (PMID: 7979199) Lancet. 2016 Apr 2;387(10026):1405-1414. (PMID: 26719230) JAMA Netw Open. 2021 Aug 2;4(8):e2119934. (PMID: 34357397) Ann Oncol. 2008 Feb;19(2):370-3. (PMID: 18156144) Lancet Oncol. 2017 Sep;18(9):1261-1273. (PMID: 28729154) J Exp Med. 2019 May 6;216(5):1016-1026. (PMID: 30975895) Arch Pathol Lab Med. 2013 May;137(5):647-67. (PMID: 22929121) Cancer Gene Ther. 2017 Mar;24(3):134-140. (PMID: 27834354) Lung Cancer. 2020 Jan;139:1-8. (PMID: 31683225) Ann Oncol. 2020 Dec;31(12):1734-1745. (PMID: 32976938) JCO Precis Oncol. 2017;2017:. (PMID: 29850653) Cancer. 1980 Dec 15;46(12):2736-40. (PMID: 7448712) J Clin Oncol. 2006 Mar 20;24(9):1443-8. (PMID: 16549838) Eur Respir J. 2006 Jun;27(6):1086-95. (PMID: 16540497) J Surg Res. 2022 Sep;277:131-137. (PMID: 35489218) Lancet Respir Med. 2019 Jul;7(7):569-580. (PMID: 31103412) J Thorac Cardiovasc Surg. 2008 Apr;135(4):823-9. (PMID: 18374762) World Neurosurg. 2018 Jan;109:362-364. (PMID: 29061454) Cancer Discov. 2021 Nov;11(11):2748-2763. (PMID: 34266984) Carcinogenesis. 2015 Jan;36(1):76-81. (PMID: 25380601) Adv Anat Pathol. 2017 Sep;24(5):235-251. (PMID: 28777142) Lancet Respir Med. 2021 Sep;9(9):969-976. (PMID: 33844995) Nat Commun. 2019 Mar 22;10(1):1333. (PMID: 30902996) J Clin Oncol. 2003 Jul 15;21(14):2636-44. (PMID: 12860938) Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421) Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. (PMID: 30459476) Cancer Discov. 2021 Nov;11(11):2738-2747. (PMID: 34261675) Nat Rev Cancer. 2018 Feb;18(2):128-134. (PMID: 29326430) Cancer Immunol Res. 2016 Nov;4(11):959-967. (PMID: 27671167) Genome Med. 2019 Feb 18;11(1):8. (PMID: 30777124) Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15-e21. (PMID: 28877075) J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075) Clin Cancer Res. 2014 Mar 1;20(5):1323-34. (PMID: 24443521) Ann Oncol. 2022 May;33(5):488-499. (PMID: 35124183) Semin Oncol. 1981 Sep;8(3):313-20. (PMID: 7280715) JAMA Netw Open. 2020 Oct 1;3(10):e2025109. (PMID: 33119110) Nat Med. 2021 Nov;27(11):1910-1920. (PMID: 34750557) Br J Cancer. 2021 Feb;124(3):564-566. (PMID: 33100328) Lung Cancer. 2009 May;64(2):211-8. (PMID: 19042053) Cell. 2009 Nov 25;139(5):871-90. (PMID: 19945376) Cancer Immunol Immunother. 2010 Oct;59(10):1543-9. (PMID: 20567822) Clin Lung Cancer. 2005 Jul;7(1):40-6. (PMID: 16098243) Eur J Cancer Prev. 2008 Nov;17(6):525-34. (PMID: 18941374) Neoplasma. 2014;61(4):433-8. (PMID: 24645844) Int J Hyperthermia. 2017 Aug;33(5):579-581. (PMID: 28664790) J Clin Invest. 2020 Jul 1;130(7):3560-3575. (PMID: 32229721) J Immunol Res. 2018 Oct 29;2018:5804230. (PMID: 30510965) Cancer Causes Control. 2009 Aug;20(6):935-44. (PMID: 19294523) Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759) JAMA Oncol. 2019 Mar 1;5(3):351-357. (PMID: 30605211) Transl Lung Cancer Res. 2018 Oct;7(5):599-608. (PMID: 30450299) Ann Oncol. 2016 Feb;27(2):225-32. (PMID: 26578726) Hum Immunol. 2006 Jan-Feb;67(1-2):1-12. (PMID: 16698419) Sci Transl Med. 2013 Aug 28;5(200):200ra116. (PMID: 23986400) MedGenMed. 2007 May 10;9(2):32. (PMID: 17955087) Ann Surg Oncol. 2020 Aug;27(8):2974-2982. (PMID: 32006127) Sci Rep. 2022 Jan 19;12(1):1007. (PMID: 35046456) Lancet Oncol. 2021 Nov;22(11):1530-1540. (PMID: 34656227) Clin Cancer Res. 2021 Sep 1;27(17):4669-4679. (PMID: 33827891) BMJ Open. 2019 May 14;9(5):e026779. (PMID: 31092657) J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) Mol Oncol. 2017 Jul;11(7):824-846. (PMID: 28614624) Lancet Respir Med. 2018 Jun;6(6):451-460. (PMID: 29773326) Carcinogenesis. 2008 Apr;29(4):673-80. (PMID: 17942460) J Transl Med. 2017 Jan 21;15(1):17. (PMID: 28109293) Respir Res. 2020 Jul 16;21(1):187. (PMID: 32677949) |
| فهرسة مساهمة: | Keywords: clinical trials; efficacy; immune checkpoint inhibitors; peritoneal mesothelioma; tumor microenvironment |
| تواريخ الأحداث: | Date Created: 20230313 Latest Revision: 20230314 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC9995593 |
| DOI: | 10.3892/mco.2023.2627 |
| PMID: | 36908980 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2049-9469 |
|---|---|
| DOI: | 10.3892/mco.2023.2627 |